东诚药业：控股子公司获177Lu - LNC1009注射液药物临床试验批准

Core Viewpoint - Dongcheng Pharmaceutical announced that its subsidiary, Lannacheng, received approval from the National Medical Products Administration for clinical trials of the 177Lu - LNC1009 injection, which is a dual-target radioactive internal therapy drug aimed at treating patients with advanced malignant solid tumors that are FAP positive and integrin αvβ positive [1] Group 1 - The clinical trial for the injection will commence soon, marking a significant step in the drug's development process [1] - The 177Lu - LNC1009 injection is currently the only product of its kind in both domestic and international markets [1] - The total research and development expenses incurred for this project amount to approximately 13.579 million yuan [1] Group 2 - The drug development process from research to market launch is lengthy and involves multiple stages, which introduces uncertainties [1]